Merck (NYSE: MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom.

The Delaware Supreme Court reportedly ruled in favor of Bayer AG BAYRY BAYZF, stating that the company is not accountable for lawsuits associated with talc-based foot powder products obtained from ...

German drugmaker Merck KGaA on Thursday joined peers in saying it was considering distribution models that serve U.S.

Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware Apr. 29, 2025 6:45 AM ET Merck & Co., Inc. (MRK) ...

Merck said last week its biggest tariff exposure is through Keytruda and it has enough U.S. inventory for this year. It estimated $200 million in additional costs for the levies implemented to date.

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Merck is seeking confirmation that Bayer is liable for talc claims that have been filed against both companies since 2014 when Bayer bought product lines from Merck in a $14 billion deal. The ...

To meet growing demand and support biologics innovation, Merck & Co., Inc. (NYSE:MRK) began construction of a $1 billion Biologics Center of Excellence in Wilmington, Delaware, in April 2025.

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market.

Akirastock By Brian Kaberline – Editor, Kansas City Business Journal Jun 29, 2020 Updated Jun 29, 2020 2:24pm CDT ...

Pharmaceutical research and development firms in China are increasingly interested in procuring critical supplies known as ...